Somali Burgess, PhD, senior director, Xcenda, discusses how patient-reported outcomes (PROs) help advance patient care and challenges with translating PROs into clinical and pharmaceutical decisions.
Somali Burgess, PhD, senior director, Xcenda, discusses how patient-reported outcomes (PROs) help advance patient care and challenges with translating PROs into clinical and pharmaceutical decisions.
Transcript
How does the incorporation of patient-reported outcomes help advance patient engagement and care?
I describe something called the 3 pillars, and the first pillar represents the registration, 1 represents reimbursement, and 1 represents brand. So, if you look at registration, patient-reported outcome (PRO) measures are included in clinical studies for registration, and so that is a direct benefit to the patient once that drug has been approved.
With reimbursement, formulary decisions are being made based on PRO data, so once that drug is put on the formulary based on that PRO data, or it’s being reimbursed, that’s another benefit to the patient because a drug is only as good as its reimbursement policy.
With the third pillar, which is brand, while it may not directly impact or prove beneficial to a patient, it is in an indirect way benefitting the patient because you do real-world studies. So, perspective studies and collecting real-world data, which is showing the burden of illness, or its showing what is happening post-approval that is going to impact patient care and patient involvement in the end.
But these are not the only ways that it can be impacted, because you’ve got studies on compliance and adherence, which are all patient reported, or measures that are used in clinical practice settings that are helping to improve patient care based on the data being generated.
Are there challenges with translating patient-reported outcomes into clinical and pharmaceutical decisions?
Yes, there’s both benefits and challenges. So, when a PRO measure is being included in a clinical trial for approval, to me that’s a direct link and a benefit, because the moment the drug is getting approved the patient is the one that’s going to be benefitting from a new drug being available, and that added value that PRO data will show. The pharmaceutical manufacturer at that point has already made the decision to include a PRO measure in a clinical study, so that is being pushed forward and really the pharmaceutical decision has been made.
But I feel like patient reported outcomes data needs to be shared more consistently with formularies and coverage decision-makers to make sure that they are showing their understanding, and therefore, making a decision based on that added value of a drug. Until the inclusion of PRO data becomes as standardized and as regular as clinical efficacy, safety, tolerability, or other economic data, we are not going to see that added value. I think the push is towards that, but it’s not there yet.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More